Nebenwirkungen · Gobivaz
GOBIVAZ 100 mg solution for injection in pre-filled syringe. · Abschnitt 4.8 · PDF-Seite 75
HOS-153572 · Präparat HOS-101000
Injection site reactions In the controlled periods of pivotal trials, 5.4% of golimumab-treated patients had injection site reactions compared with 2.0% in control patients. The presence of antibodies to golimumab may increase the risk of injection site reactions. The majority of the injection site reactions were mild and moderate and the most frequent manifestation was injection site erythema. Injection site reactions generally did not necessitate discontinuation of the medicinal product.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T10:38:00Z · SHA-256 b368a4f3ae6dce5887430617ccfcdc36900996af800ff08514415b29e19f2102 · Passage 47bbd7fa26cdfc1e95d10f7559467583ad2a4525a0bfbe9aed4965da4bfec78d · Zeichen 16319–16813 im Abschnitt